聚乙二醇化干扰素α-2a在非治疗随访期间和治疗后48周内对HBe

StephenW

Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg
Shima Mimura  1 , Koji Fujita  2 , Kei Takuma  2 , Mai Nakahara  2 , Kyoko Oura  2 , Tomoko Tadokoro  2 , Hideki Kobara  2 , Joji Tani  2 , Asahiro Morishita  2 , Takashi Himoto  3 , Tsutomu Masaki  2
Affiliations
Affiliations

    1
    Department of Gastroenterology and Neurology, Kagawa University Hospital, Ikenobe Miki-cho, Kita-gun, Kagawa, 761-0793, Japan. [email protected].
    2
    Department of Gastroenterology and Neurology, Kagawa University Hospital, Ikenobe Miki-cho, Kita-gun, Kagawa, 761-0793, Japan.
    3
    Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa, Japan.

    PMID: 33502731 DOI: 10.1007/s11739-020-02622-7

Abstract

Hepatitis B virus (HBV) infection is a major public health problem worldwide. The study aimed to evaluate the efficacy of pegylated interferon (Peg-IFN) alfa-2a treatment for seroclearance of HBs antigen (HBsAg) in HBe antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. This retrospective study investigated 16 HBeAg-negative CHB patients who received Peg-IFN alfa-2a weekly for 48 weeks. Thereafter, the patients were followed-up for 48 weeks after the end of therapy. The following criteria were also used for inclusion: HBV-DNA < 5.0 log copies/mL and without nucleot(s)ide analogs. Four HBsAg-positive cases became HBsAg negative. The HBsAg levels of the 4 patients who achieved HBsAg seroclearance were lower significantly than that of the non-seroclearance group (p = 0.007). The mean HBsAg levels in these 4 cases were 68 IU/mL, while the mean HBsAg levels in the non-seroclearance group were 2,114 IU/mL. The mean HBV-DNA levels in the 4 HBsAg seroclearance cases were 2.8 log copies/mL as compared to 3.6 log copies/mL in HBsAg-non-seroclearance cases (p = 0.01). Cases that are HBeAg negative, with HBV-DNA levels < 5 log copies/mL, and HBsAg titers < 120 IU/mL cases may achieve HBsAg clearance with Peg-IFN therapy.

Keywords: Chronic hepatitis B; HBeAg negative; HBsAg; Peg-IFN.

StephenW

聚乙二醇化干扰素α-2a在非治疗随访期间和治疗后48周内对HBeAg阴性慢性乙型肝炎的影响：治疗前HBsAg负荷对HBsAg血清清除的限制
志摩三村1，藤田康司2，藤田圭2，中原麻衣2，大浦恭子2，桃子智多郎2，小原秀树2，谷谷次二2，森下朝弘2，高桥智本3，武藤正明2
隶属关系
隶属关系

    1个
    日本香川县北田郡池部三木町香川大学医院消化内科和神经内科，日本761-0793。 [email protected]。
    2
    日本香川县北田郡池部三木町香川大学医院消化内科和神经内科，日本761-0793。
    3
    日本香川县立健康科学大学医疗技术系。

    PMID：33502731 DOI：10.1007 / s11739-020-02622-7

抽象

乙型肝炎病毒（HBV）感染是全球主要的公共卫生问题。该研究旨在评估聚乙二醇干扰素（Peg-IFN）alfa-2a治疗HBe抗原（HBeAg）阴性的慢性乙型肝炎（CHB）患者的HBs抗原（HBsAg）血清清除的疗效。这项回顾性研究调查了16名HBeAg阴性CHB患者，他们每周接受Peg-IFN alfa-2a治疗48周。此后，在治疗结束后对患者进行了48周的随访。还包括以下标准：HBV-DNA <5.0 log拷贝/ mL，无核苷酸类似物。 4例HBsAg阳性病例变为HBsAg阴性。达到HBsAg血清清除率的4例患者的HBsAg水平显着低于非血清清除组（p = 0.007）。这4例患者的平均HBsAg水平为68 IU / mL，而无血清清除组的平均HBsAg水平为2,114 IU / mL。 4例HBsAg血清清除病例的平均HBV-DNA水平为2.8 log拷贝/ mL，而非HBsAg非血清清除病例为3.6 log拷贝/ mL（p = 0.01）。 HBV-DNA水平<5 log拷贝/ mL且HBsAg滴度<120 IU / mL的HBeAg阴性病例可通过Peg-IFN治疗达到HBsAg清除率。

关键字：慢性乙型肝炎； HBeAg阴性；乙肝表面抗原PEG-IFN。